Benjamin Bonavida
Benjamin Bonavida
Bevin P Engleward
Bevin P Engleward
Benjamin Bonavida
Benjamin Bonavida
From Research to the Real World: Moving Prostate Cancer Biomarkers into the Clinic [0.03%]
从科研到临床：推动前列腺癌生物标志物的发展
Kate Mahon
Kate Mahon
Effective biomarkers provide the potential to significantly improve treatment decisions and outcomes in prostate cancer patients. While the literature is inundated with prostate cancer biomarkers in the early phases of testing, very few rea...
Technologies for Size-Based Analysis of Circulating Cell-Free DNA: Limitations and Clinical Implementation [0.03%]
基于尺寸分析的循环细胞游离DNA的技术限制及临床应用
Thomas Pataillot-Meakin,Sylvain Ladame,Charlotte Bevan
Thomas Pataillot-Meakin
Prostate cancer is the second most common malignancy in men worldwide, and incidence is likely to rise in the next decade. The current screening options have limitations and have been shown to result in over-treatment of clinically insignif...
Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer [0.03%]
BRCA2改变作为前列腺癌治疗反应决定因素的作用
Mia Hofstad,Emily Y Huang,Andrea Woods et al.
Mia Hofstad et al.
Prostate cancer (PCa) is one of the leading causes of cancer diagnoses and cancer-related deaths in the United States. Mutations or deletions in the genes involved in the DNA damage response (DDR) are common in aggressive primary PCa (germl...
Genomic Alterations to Guide Treatment Selection in Metastatic Prostate Cancer [0.03%]
转移性前列腺癌的精准医疗：基于基因组改变指导治疗选择
Amy Davies,Arun A Azad,Edmond M Kwan
Amy Davies
Treatment options for men with metastatic prostate cancer have greatly expanded in the last decade. Androgen receptor pathway inhibitors, taxane cytotoxic therapy, poly(ADP-ribose) polymerase inhibitors, and radionuclide theranostics agains...
Phenotypic Plasticity - Alternate Transcriptional Programs Driving Treatment Resistant Prostate Cancer [0.03%]
表型可塑性-驱动难治性前列腺癌的替代转录谱系
Jagpreet Singh Nanda,Praveen Koganti,Graziela Perri et al.
Jagpreet Singh Nanda et al.
Androgen deprivation therapy (ADT) that antagonizes androgen receptor (AR) signaling has made significant increases to overall survival of prostate cancer patients. However, ADT is not curative, and patients eventually progress to castratio...
The Challenges and Emerging Opportunities of Targeting Cytokines and Chemokine-Driven Inflammatory Signals in Metastatic Castrate-Resistant Prostate Cancer [0.03%]
瞄准转移性去势抵抗性前列腺癌细胞因子和化学趋向因子驱动的炎症信号所面临的挑战及新兴机遇
David J J Waugh,Jacqui A McGovern,Suzanne McCusker
David J J Waugh
Inflammation is a key risk factor and functional driver in the initiation and progression of prostate cancer (PCa). De-regulated cytokine and chemokine signaling facilitates critical communication between tumor cells and multiple cell linea...
Novel Therapeutic Targets and Biomarkers Associated with Prostate Cancer-Associated Fibroblasts (CAFs) [0.03%]
与前列腺癌相关肌成纤维细胞（CAFs）相关的新型治疗靶点和生物标志物
Kimberley C Clark,Yunjian Wu,Renea A Taylor et al.
Kimberley C Clark et al.
Despite advances in treatment, prostate cancer remains a significant cause of morbidity and mortality worldwide. While the vast majority of prostate cancer research has centered on malignant epithelial cells, the tumor mi croenvironment (TM...